Decreased levels of nitric oxide production and nitric oxide synthase-2 expression are associated with the development and metastasis of hepatocellular carcinoma

Zhou,Lei; Wang,Ying; Tian,De-An; Yang,Juan; Yang,Yu-Zhen

doi:10.3892/mmr.2012.1096

Decreased levels of nitric oxide production and nitric oxide synthase-2 expression are associated with the development and metastasis of hepatocellular carcinoma

Authors:
- Lei Zhou
- Ying Wang
- De-An Tian
- Juan Yang
- Yu-Zhen Yang
View Affiliations

Affiliations: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China
Published online on: September 24, 2012 https://doi.org/10.3892/mmr.2012.1096
Pages: 1261-1266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Many studies have demonstrated the function of nitric oxide (NO) or nitric oxide synthase-2 (NOS-2) in cancer as pro-neoplastic or anti-neoplastic effectors, but the role of NO and NOS-2 in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the levels of NO production and NOS-2 expression in HCC and adjacent non-tumor liver tissues and to clarify whether the levels of NO/NOS-2 are related to the clinicopathological features of HCC. The levels of NO production were examined in tumor and adjacent non-tumor liver tissues of 30 patients with HCC. The expression of NOS-2 was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemical analysis in HCC and/or adjacent non-tumor liver tissues. Mutant p53 and proliferating cell nuclear antigen (PCNA) were also immunohistochemically investigated in liver tissues. The levels of NO in HCC were significantly lower compared to adjacent non-tumor liver tissues (P<0.001). The relative mRNA and protein expression levels of NOS-2 in HCC were also significantly lower compared to adjacent non-tumor liver tissues (P<0.01 for both). We found that the levels of NO in patients suffering from HCC metastasis were lower compared to those without metastasis (P<0.05) and NOS-2 expression was correlated with tumor diameter (P<0.05) and metastasis (P<0.05). In addition, mutant p53 protein was expressed in the majority of HCC samples and the proliferation rate of HCC was significantly higher than that of adjacent non-tumor liver tissues. These data indicate that decreased levels of NO/NOS-2 may partially contribute to overexpression of the mutant p53 protein and excessive proliferation; this may be a potential mechanism in the development and progression of HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491. 2009. View Article : Google Scholar : PubMed/NCBI
3	Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E and LaVecchia C: Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology. 48:137–145. 2008.
4	Adachi E, Maeda T, Matsumata T, et al: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 108:768–775. 1995. View Article : Google Scholar : PubMed/NCBI
5	Kroncke KD, Fehsel K and Kolb-Bachofen V: Inducible nitric oxide synthase in human diseases. Clin Exp Immunol. 113:147–156. 1998. View Article : Google Scholar : PubMed/NCBI
6	Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
7	Ambs S, Merriam WG, Bennett WP, et al: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58:334–341. 1998.PubMed/NCBI
8	Ekmekcioglu S, Ellerhorst J, Smid CM, et al: Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 6:4768–4775. 2000.PubMed/NCBI
9	Masri FA, Comhair SA, Koeck T, et al: Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 172:597–605. 2005. View Article : Google Scholar : PubMed/NCBI
10	Huerta S, Chilka S and Bonavida B: Nitric oxide donors: novel cancer therapeutics (Review). Int J Oncol. 33:909–927. 2008.PubMed/NCBI
11	Shaulsky G, Goldfinger N and Rotter V: Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51:5232–5237. 1991.PubMed/NCBI
12	Bonavida B and Baritaki S: Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kB/Snail/YY1/RKIP circuitry. Nitric Oxide. 24:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
13	Hickok JR, Sahni S, Mikhed Y, Bonini MG and Thomas DD: Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J Biol Chem. 286:41413–41424. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D and Yeung K: Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide. 19:152–157. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hussain SP, Trivers GE, Hofseth LJ, et al: Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res. 64:6849–6853. 2004. View Article : Google Scholar : PubMed/NCBI
16	Le X, Wei D, Huang S, Lancaster JR Jr and Xie K: Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci USA. 102:8758–8763. 2005. View Article : Google Scholar : PubMed/NCBI
17	Thilakawardhana S, Everett DM, Murdock PR, Dingwall C and Owen JS: Quantification of apolipoprotein E receptors in human brain-derived cell lines by real-time polymerase chain reaction. Neurobiol Aging. 26:813–823. 2005. View Article : Google Scholar
18	Yang XR, Xu Y, Yu B, et al: CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 15:5518–5527. 2009. View Article : Google Scholar : PubMed/NCBI
19	Rahman MA, Dhar DK, Yamaguchi E, et al: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 7:1325–1332. 2001.
20	Wei D, Richardson EL, Zhu K, et al: Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res. 63:3855–3859. 2003.PubMed/NCBI
21	Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H and Baba H: Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res. 8:1152–1163. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G and Sacchi A: Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI